Top-Rated StocksTop-RatedNASDAQ:ACLX Arcellx (ACLX) Stock Price, News & Analysis $64.41 +1.72 (+2.74%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$62.36▼$64.7150-Day Range$50.45▼$65.9252-Week Range$30.88▼$75.10Volume264,422 shsAverage Volume459,583 shsMarket Capitalization$3.45 billionP/E RatioN/ADividend YieldN/APrice Target$78.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arcellx alerts: Email Address Arcellx MarketRank™ Stock AnalysisAnalyst RatingBuy3.07 Rating ScoreUpside/Downside21.1% Upside$78.00 Price TargetShort InterestBearish12.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 9 Articles This WeekInsider TradingSelling Shares$6.01 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.70) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector764th out of 936 stocksBiological Products, Except Diagnostic Industry130th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingArcellx has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcellx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcellx's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.47% of the float of Arcellx has been sold short.Short Interest Ratio / Days to CoverArcellx has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Arcellx has recently increased by 4.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArcellx does not currently pay a dividend.Dividend GrowthArcellx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACLX. Previous Next 2.6 News and Social Media Coverage News SentimentArcellx has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Arcellx this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows3 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,008,891.00 in company stock.Percentage Held by InsidersOnly 6.24% of the stock of Arcellx is held by insiders.Percentage Held by Institutions96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcellx's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arcellx are expected to decrease in the coming year, from ($1.70) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcellx is -62.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcellx is -62.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcellx has a P/B Ratio of 6.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcellx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Arcellx Stock (NASDAQ:ACLX)Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More ACLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACLX Stock News HeadlinesJuly 20, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Sells $711,835.30 in StockJuly 13, 2024 | insidertrades.comChristopher Heery Sells 3,671 Shares of Arcellx, Inc. (NASDAQ:ACLX) StockJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 13, 2024 | insidertrades.comKavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) StockJuly 4, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Sells $1,107,800.00 in StockJune 29, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 10,000 SharesJuly 23 at 5:17 PM | ca.finance.yahoo.comACLX Aug 2024 60.000 putJuly 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Arcellx Inc for Its Innovative Multiple Myeloma Treatments and Competitive Market PositionJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 22, 2024 | markets.businessinsider.comDecoding 8 Analyst Evaluations For ArcellxJuly 22, 2024 | americanbankingnews.comCanaccord Genuity Group Reiterates Buy Rating for Arcellx (NASDAQ:ACLX)July 17, 2024 | americanbankingnews.comArcellx, Inc. (NASDAQ:ACLX) Receives $78.00 Consensus Price Target from BrokeragesJuly 4, 2024 | investorplace.comFDA Favorites: 3 Biotech Stocks on the Verge of Major ApprovalsJune 26, 2024 | seekingalpha.comArcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma MarketMay 27, 2024 | investorplace.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 25, 2024 | finance.yahoo.comInsider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX)May 17, 2024 | uk.investing.comArcellx shares target raised by Stifel on study designMay 14, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)See More Headlines Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACLX CUSIPN/A CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$78.00 High Stock Price Target$87.00 Low Stock Price Target$52.00 Potential Upside/Downside+21.8%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,690,000.00 Net Margins-38.39% Pretax Margin-38.13% Return on Equity-13.11% Return on Assets-7.11% Debt Debt-to-Equity RatioN/A Current Ratio5.46 Quick Ratio5.46 Sales & Book Value Annual Sales$110.32 million Price / Sales31.06 Cash FlowN/A Price / Cash FlowN/A Book Value$9.97 per share Price / Book6.42Miscellaneous Outstanding Shares53,500,000Free Float50,164,000Market Cap$3.43 billion OptionableOptionable Beta0.23 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Rami Elghandour (Age 45)Chairman of the Board, CEO & President Comp: $1.02MMs. Michelle Lim Gilson (Age 31)Chief Financial Officer Comp: $832.8kDr. Christopher R. Heery M.D. (Age 44)Chief Medical Officer Comp: $688.55kMr. Narinderjeet Singh M.S. (Age 52)Chief Technical Officer Mr. David Tice Ph.D. (Age 53)Chief Scientific Officer Ms. Myesha LacyChief Investor & Communications OfficerMs. Maryam Abdul-Kareem J.D.M.S., General CounselMs. Kate AikenChief People OfficerMr. Neeraj P. Teotia (Age 49)Chief Commercial Officer Comp: $461.95kMs. Aileen FernandesChief Business OfficerMore ExecutivesKey CompetitorsDr. Reddy's LaboratoriesNYSE:RDYCatalentNYSE:CTLTQiagenNYSE:QGENRoivant SciencesNASDAQ:ROIVLantheusNASDAQ:LNTHView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 26,134 shares on 7/26/2024Ownership: 0.275%Allspring Global Investments Holdings LLCBought 4,372 shares on 7/26/2024Ownership: 0.030%China Universal Asset Management Co. Ltd.Sold 3,890 shares on 7/20/2024Ownership: 0.012%Christopher HeerySold 10,901 sharesTotal: $711,835.30 ($65.30/share)Christopher HeerySold 3,671 sharesTotal: $220,296.71 ($60.01/share)View All Insider TransactionsView All Institutional Transactions ACLX Stock Analysis - Frequently Asked Questions How have ACLX shares performed this year? Arcellx's stock was trading at $55.50 at the start of the year. Since then, ACLX stock has increased by 16.1% and is now trading at $64.41. View the best growth stocks for 2024 here. How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) posted its earnings results on Thursday, May, 9th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.37. The business's revenue was up 119.2% compared to the same quarter last year. When did Arcellx IPO? Arcellx (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share. Who are Arcellx's major shareholders? Arcellx's top institutional shareholders include Bank of New York Mellon Corp (0.28%), Harbor Capital Advisors Inc. (0.04%), Allspring Global Investments Holdings LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Enterprise Associates 15 New, Sr One Capital Management, Llc, Jill Carroll, Rami Elghandour, Christopher Heery, Michelle Gilson, Olivia C Ware and Kavita Patel. View institutional ownership trends. How do I buy shares of Arcellx? Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACLX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
